KPRX Archives - BioTuesdays

Developments

Kiora RP treatment seen restoring visual function in blind patients

Kiora Pharmaceuticals (NASDAQ:KPRX) presented preliminary results from an ongoing clinical trial, showing that its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind...

April 28, 2023

Developments

Kiora initiates Phase 2 Trial for ocular presentation of autoimmune diseases

Kiora Pharmaceuticals (NASDAQ:KPRX) enrolled the first patient in its Phase 2 trial of KIO-101 in the treatment of the ocular presentations of rheumatoid arthritis and other autoimmune diseases. The multi-center...

April 17, 2023

Developments

Kiora completes enrollment in persistent corneal epithelial defects trial

Kiora Pharmaceuticals (NASDAQ:KPRX) completed enrollment in its clinical study evaluating KIO-201 in patients with persistent corneal epithelial defects (PCED), a rare ocular condition characterized by non-healing...

January 3, 2023

Developments

Kiora doses first patient in Phase 1b retinitis pigmentosa trial

Kiora Pharmaceuticals (NASDAQ:KPRX) dosed the first patient in a first-in-human open-label clinical trial for KIO-301, intended to restore vision loss in patients with retinitis pigmentosa, a rare, inherited genetic eye...

November 17, 2022

Feature

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Kiora Pharmaceuticals (NASDAQ:KPRX) expects to release Phase 1b interim data at the beginning of 2023 from its flagship intravitreal injection to potentially restore vision in patients with retinitis pigmentosa, a rare...

September 27, 2022

Markets

Ladenburg starts Kiora Pharma at buy; PT $6.50

Ladenburg Thalmann initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $6.50. The stock closed at 13 cents on Aug. 24. Kiora is focused on bringing treatments to the market...

August 25, 2022

Markets

Maxim reduces PTs in challenging biotech market

Maxim Group analyst Jason McCarthy, Ph.D., reduced price targets for 13 stocks in his coverage universe, citing macroeconomic winds and a significant decline in stock prices, particularly for small-cap biotech stocks...

May 26, 2022

Markets

Maxim starts Kiora Pharma at buy; PT $2.50

Maxim Group initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $2.50. The stock closed at 80 cents on Jan. 18. Kiora is developing ophthalmic medicines including, KIO-101...

January 19, 2022

Tag - KPRX

Kiora RP treatment seen restoring visual function in blind patients

Kiora initiates Phase 2 Trial for ocular presentation of autoimmune diseases

Kiora completes enrollment in persistent corneal epithelial defects trial

Kiora doses first patient in Phase 1b retinitis pigmentosa trial

Kiora Pharma eyes novel approach to vision restoration in retinitis pigmentosa

Ladenburg starts Kiora Pharma at buy; PT $6.50

Maxim reduces PTs in challenging biotech market

Maxim starts Kiora Pharma at buy; PT $2.50

General

More